Product Code: IRTNTR8630
About Peptide Therapeutics
Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual's physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications.
Technavio's analysts forecast the global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases.
The market is divided into the following segments based on geography:
Technavio's report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Eli Lilly
- Novo Nordisk
- Sanofi
- Takeda Pharmaceutical
- Teva Pharmaceuticals
Other Prominent Vendors
- AbbVie
- Advanced Accelerator Applications
- Akashi Therapeutics
- Amgen
- Anthera Pharmaceuticals
- AstraZeneca
- Bachem
- Bristol-Myers Squibb
- Cardiorentis
- Corden Pharma International
- Debiopharm
- Derma Sciences
- GlaxoSmithKline
- Hanmi Pharmaceutical
- Insmed
- Ipsen
- Johnson & Johnson
- Lonza
- Mallinckrodt
- MolMed
- Merck
- Novartis
- Nymox Pharmaceutical
- Par Pharmaceuticals
- PeptiDream
- Polypeptide Group
- Radius Health
- Repligen
- Roche
- SciClone
- Shire
- The Medicines Company
- Transition Therapeutics
- X-Gen Pharmaceuticals
- Zealand Pharma
- Zydus Cadila
Market driver
- Increase in patient population
- For a full, detailed list, view our report
Market challenge
- High cost of therapy
- For a full, detailed list, view our report
Market trend
- Shifting focus toward untapped markets
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Overview of peptides
- Peptide synthesis
- Optimization of peptides
- Stabilization of peptides
- PART 06: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 07: Market segmentation based on route of administration
- Parenteral
- Oral
- Pulmonary
- Mucosal
PART 08: Market segmentation by drug class
- Somatostatins
- Vasopressin
- Calcitonins
- Luteinizing hormone (LH)-releasing hormone (LHRH)
- Glucagon and analogs
- Insulins
- Other
PART 09: Market segmentation by synthesis technology
- Liquid-phase peptide synthesis
- Solid-phase peptide synthesis
- Hybrid peptide synthesis
PART 10: Geographical segmentation
- Global peptide therapeutics market segmentation by geography 2015-2020
- Peptide therapeutics market in Americas
- Peptide therapeutics market in EMEA
- Peptide therapeutics market in APAC
PART 11: Market drivers
- Increase in patient population
- Advances in peptide synthesis technology
- Promising pipeline
- Unmet medical needs
- Increase in healthcare spending
PART 12: Impact of drivers
PART 13: Market challenges
- High cost of therapy
- Adverse side effects
- Stringent regulatory compliances
- Intense market competition
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Growing popularity
- Shifting focus toward untapped markets
- Contract manufacturing
- Increase in public awareness
PART 16: Vendor landscape
- Competitive scenario
- Eli Lilly
- Novo Nordisk
- Sanofi
- Takeda Pharmaceutical
- Teva Pharmaceuticals
- Other prominent vendors
PART 17: Appendix
PART 18: Explore Technavio
List of Exhibits
- Exhibit 01: Product offerings
- Exhibit 02: SWOT analysis: Peptide therapeutics
- Exhibit 03: Steps involved in peptide synthesis
- Exhibit 04: Optimization of peptide synthesis
- Exhibit 05: Methods used to stabilize peptides
- Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
- Exhibit 07: Five forces analysis
- Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
- Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
- Exhibit 10: Global peptide therapeutics market segmentation by drug class
- Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
- Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
- Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
- Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
- Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
- Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
- Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
- Exhibit 18: Impact of drivers
- Exhibit 19: Impact of drivers and challenges
- Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
- Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
- Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
- Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
- Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
- Exhibit 25: Eli Lilly: Key takeaways
- Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
- Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
- Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
- Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
- Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
- Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
- Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
- Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
- Exhibit 34: Novo Nordisk: Key takeaways
- Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
- Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
- Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
- Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
- Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
- Exhibit 40: Sanofi: Key takeaways
- Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
- Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
- Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
- Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
- Exhibit 45: Takeda Pharmaceutical: Key takeaways
- Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
- Exhibit 47: Teva Pharmaceuticals: Key takeaways
